Cure My Disease

Don't miss your cure!

 Log in / Sign up

Banked t cells target four viruses at once in children after transplant

NCT ID NCT07104591

Cure Sponsor: Baylor College of Medicine Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access This study
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 15, 2026 · Last updated Sep 16, 2026 · Updated 1 time

Summary

This expanded access program lets doctors in Texas give banked, partially matched virus-specific T cells to children under 18 who have persistent or recurring EBV, CMV, adenovirus, or BK virus infections after an allogeneic stem cell transplant or CAR T therapy. The cells come from Baylor College of Medicine's TETRAVI program and are directed against all four viruses. The program is for children who have no other suitable treatment options.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
banked, partially HLA-matched virus-specific T cells (VSTs) that target EBV, CMV, adenovirus, and BK virus
What this could lead to
If it works, this could give children with hard-to-treat viral infections after a stem cell transplant a ready-made cell therapy option when standard antiviral drugs fail.
What could go wrong
This is an expanded access program, not a controlled trial, so it cannot prove the cells work. The banked cells are only partially matched to each child, which may limit how well they fight the infection, and some viral infections may not respond.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Up to 17 years

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients \<18 years of age. * Patients who have undergone myeloablative or non-myeloablative allogeneic HSCT or CAR T therapy in the Sate of Texas (USA). * Have persistent, increasing, or recurrent infections with EBV, CMV, adenovirus, or BK virus despite standard treatment. * Treating physician must be based in Texas. * Must obtain IRB approval and submit a protocol to FDA with Letter of Authorization from Baylor. Exclusion Criteria: * Patients with active uncontrolled infections unrelated to the viruses mentioned. * Use of certain immunosuppressive agents within 28 days. * Serious uncontrolled medical conditions or relapse of underlying disease.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Adenovirus infection are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adenoviridae infectious disease BK-virus nephropathy cytomegalovirus infection Epstein-Barr virus infection polyomavirus infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Adenovirus infection BK virus infection Cytomegalovirus infections Epstein-Barr virus infection JC virus infection Post-allogeneic stem cell transplant complications Viral infections post-transplant

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.